NFKB1 and prostate cancer: p50‐IMC develop into both TAMs and DCs in vivo, and IMC localize strongly to prostate cancer and pancreatic ductal carcinoma tumors, with tumor localization ~ 2.5‐fold higher than spleen or lung with minimal liver localization [17].